Itoh Y, Okanoue T, Sakamoto S, Nishioji K, Kashima K, Ohmoto Y
Third Department of Internal Medicine, Kyoto Prefectural University of Medicine, Japan.
Am J Gastroenterol. 1995 May;90(5):777-82.
To clarify the clinical significance of serum levels of interleukin-1 alpha autoantibody in liver disease and their change during interferon therapy for chronic hepatitis.
By radioimmunoassay, we studied the incidence of serum interleukin-1 alpha autoantibody in 838 healthy controls and 180 patients with liver disease and monitored the change in antibody titer during the interferon therapy for chronic hepatitis.
We detected the interleukin-1 alpha autoantibody in 12.6% (106/838) of healthy controls. In patients with liver disease, we found the antibody in 15.6% (5/32) in patients with acute hepatitis, 16.3% (13/80) in patients with chronic hepatitis, 18.8% (9/48) in patients with liver cirrhosis, and 15% (3/20) in patients with autoimmune liver disease. The incidence was not related to either etiology or inflammatory activity of liver disease. Two of three chronic hepatitis patients with initially high serum levels of the antibody (> 2000 ng/ml) showed transient increase in antibody titers during interferon therapy.
The serum level of interleukin-1 alpha autoantibody was unrelated to the etiology or activity of liver disease. Interferon therapy can cause transient elevation of serum interleukin-1 alpha autoantibody levels.
阐明血清白细胞介素-1α自身抗体水平在肝脏疾病中的临床意义及其在慢性肝炎干扰素治疗期间的变化。
采用放射免疫分析法，我们研究了838名健康对照者和180例肝脏疾病患者血清白细胞介素-1α自身抗体的发生率，并监测了慢性肝炎干扰素治疗期间抗体滴度的变化。
我们在12.6%（106/838）的健康对照者中检测到白细胞介素-1α自身抗体。在肝脏疾病患者中，急性肝炎患者中有15.6%（5/32）检测到该抗体，慢性肝炎患者中有16.3%（13/80），肝硬化患者中有18.8%（9/48），自身免疫性肝病患者中有15%（3/20）。该发生率与肝脏疾病的病因或炎症活动均无关。三名初始血清抗体水平较高（>2000 ng/ml）的慢性肝炎患者中有两名在干扰素治疗期间抗体滴度出现短暂升高。
血清白细胞介素-1α自身抗体水平与肝脏疾病的病因或活动无关。干扰素治疗可导致血清白细胞介素-1α自身抗体水平短暂升高。
